At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 128 enrolled
Drug / intervention
BI 409306 +8 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-centre, Double-blind, Parallel-group, Randomized Controlled Study to Investigate the Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Alzheimer Disease
In Brief
A Phase 2 clinical trial evaluating BI 409306 and Placebo for Alzheimer Disease. Completed, enrolled 128 participants across 52 sites in 12 countries.
Detailed Summary
The study is designed to compare the effects of 4 different doses of orally administered BI 409306 to placebo in patients with Alzheimers Disease
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesAustria, Belgium, Canada, France, Germany, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartJan 2015
Primary CompletionSep 2017
Study CompletionOct 2017
TodayJul 2026
First PostedSep 16, 2014
Enrollment StartJan 15, 2015
Primary CompletionSep 18, 2017
Study CompletionOct 9, 2017
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.8 years ago
Interventions
BI 409306drug
Placebodrug
BI 409306drug
Placebodrug
Placebodrug
BI 409306drug
BI 409306drug
Placebodrug
Placebodrug